Grimes & Company Inc. Takes Position in Hologic, Inc. $HOLX

Grimes & Company Inc. acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor acquired 3,181 shares of the medical equipment provider’s stock, valued at approximately $207,000.

Other institutional investors have also recently modified their holdings of the company. Zions Bancorporation National Association UT bought a new position in shares of Hologic during the 1st quarter valued at about $34,000. Cromwell Holdings LLC boosted its holdings in Hologic by 307.0% during the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 436 shares during the period. Allworth Financial LP boosted its holdings in Hologic by 46.0% during the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock valued at $40,000 after acquiring an additional 216 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in Hologic during the 1st quarter valued at about $42,000. Finally, Larson Financial Group LLC boosted its holdings in Hologic by 6,016.7% during the 1st quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 722 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the transaction, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at approximately $82,682,769.28. This represents a 10.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 1.88% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on HOLX shares. Mizuho set a $75.00 target price on Hologic in a report on Thursday, July 31st. Evercore ISI set a $78.00 target price on Hologic and gave the company an “outperform” rating in a report on Tuesday. Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and increased their target price for the company from $60.00 to $80.00 in a report on Wednesday, July 9th. Stephens restated an “overweight” rating and set a $78.00 target price on shares of Hologic in a report on Thursday, September 18th. Finally, Wall Street Zen cut Hologic from a “buy” rating to a “hold” rating in a report on Wednesday, October 1st. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $80.15.

Hologic Stock Up 0.6%

Shares of NASDAQ:HOLX opened at $67.73 on Wednesday. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.39. The firm has a market capitalization of $15.06 billion, a P/E ratio of 28.10, a P/E/G ratio of 2.31 and a beta of 0.63. The stock has a 50 day moving average price of $67.03 and a 200-day moving average price of $63.18. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same quarter in the prior year, the company earned $1.06 EPS. The business’s revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, equities research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.